Overview of Dr. Tsao
Che-Kai Tsao, MD is the Medical Director of the Ruttenberg Treatment Center and the Medical Oncology Prostate Cancer Program at the Tisch Cancer Institute, Mount Sinai Hospital. His mission in this role is to lead this multi-disciplinary treatment center in delivering the highest quality of scientifically innovative and patient centered care to those affected by cancer and blood disorders.
He is an Associate Professor of Medicine, Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai and is on staff at the Tisch Cancer Institute of the Mount Sinai Hospital. He is actively involved in research on the development of novel therapies in the treatment of genitourinary cancers. His main focus is in defining clinical and molecular phenotype of prostate, kidney, and bladder cancers, as well as novel therapies in those disease states.
Office
1470 Madison Avenue, Ruttenberg Treatment Center
Mount Sinai Medical Center
New York, NY 10029- Is this information wrong?
Education & Training
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2009 - 2012
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 2005 - 2008
State University of New York Downstate Medical Center College of MedicineClass of 2005
New York UniversityB.A., Mathematics and Economics, Cum Laude, 1996 - 2000
Certifications & Licensure
NY State Medical License 2008 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Solid Tumor Faculty Teacher of the Year Tisch Cancer Institute, 2023
- Fellow Physician of the Year Mount Sinai Hospital, 2012
- Merit Award American Society of Clinical Oncology, 2012
- Join now to see all
Clinical Trials
- A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney Start of enrollment: 2017 Jul 07
- A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) Start of enrollment: 2018 Dec 18
- A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Start of enrollment: 2019 Aug 12
- Join now to see all
Publications & Presentations
PubMed
- Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.Parissa Alerasool, Noriko Kishi, Himanshu Joshi, Susu Zhou, Gagan Sahni, Che-Kai Tsao> ;Clinical Genitourinary Cancer. 2024 Mar 8
- Risk Factors for Early Treatment Discontinuation Due to Toxicity Among Patients With Metastatic Castration-resistant Prostate Cancer Receiving Androgen Receptor-target...Chakrani, Z., Saffran, N., McCroskery, S., Taylor, N., Patel, M., Mellgard, G., Liaw, B., Galsky, M., Oh, W., Tsao, C., Patel, V.> ;American Journal of Clinical Oncology. 2024 Feb 12
- Clinical Significance of Extracellular Vesicles in Prostate and Renal Cancer.Tzu-Yi Chen, Meredith Mihalopoulos, Laura Zuluaga, Jordan Rich, Teja Ganta, Reza Mehrazin, Che-Kai Tsao, Ash Tewari, Edgar Gonzalez-Kozlova, Ketan Badani, Navneet Dogr...> ;International Journal of Molecular Sciences. 2023 Sep 28
- Join now to see all
Journal Articles
- Activity of Platinum-Based Chemotherapy in Patients with Advanced Prostate Cancer with and Without DNA Repair Gene AberrationsHimisha Beltran, Che-Kai Tsao, Tomasz M Beer, JAMA Network Open
- Endocrine therapy for prostate cancer: review of the latest clinical evidenceTsao CK, Seng SM, Galsky MD, Oh WK, Clinical Investigation, 4/1/2011
- Review of cabazitaxel for the treatment of hormone-refractory prostate cancerTsao CK, Seng SM, Oh WK, Galsky MD, Clinical Medicine Insights: Oncology, 1/1/2011
- Join now to see all
Press Mentions
Study on Veterans Reveals Real-World Survival Outcomes for Targeted Therapies in Advanced Renal Cell CarcinomaNovember 18th, 2019
Nivolumab Trial Failure Raises the Question of Brain Imaging in Kidney CancerJuly 8th, 2019- JAVELIN Renal 101: Combination Therapy vs Standard of Care in Advanced RCCMarch 6th, 2019
Professional Memberships
- Member
- Member
Other Languages
- Chinese (Mandarin), Taiwanese
Hospital Affiliations
The Mount Sinai HospitalNew York, New York- The Mount Sinai HospitalNew York, New York
- The Mount Sinai HospitalNew York, New York
- The Mount Sinai HospitalNew York, New York
Mount Sinai Hospital of QueensAstoria, New York
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPOGHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
